Journal of Clinical Oncology
Articles in this Issue
Trends in renal cell carcinoma mortality associated with tobacco use in U.S. adults aged ≥45 years, 1999–2023: A population-based CDC WONDER analysis.
434 Background: Renal cell carcinoma (RCC) is one of the common malignancies in the United States. Tobacco exposure is an...
EGFR, HER2 alterations in advanced urothelial carcinoma (aUC): A retrospective analysis on survival outcomes.
787 Background: EGFR alterations (EGFR-alt) and HER2 alterations (ERBB2-alt) are each seen in approximately 4% of advanced...
Clinical and social determinants of definitive surgical management in bladder cancer: A two-decade population-based analysis from the United States.
654 Background: Surgical management of bladder cancer ranges from bladder-preserving approaches to radical cystectomy. We...
Disitamab vedotin plus PD-1 inhibitors as neoadjuvant therapy for cisplatin-ineligible muscle-invasive bladder cancer: A real-world retrospective study.
691 Background: Cisplatin-based neoadjuvant chemotherapy (NAC) remains the standard for muscle-invasive bladder cancer (MI...
Development of cardiovascular disease risk factors in patients with prostate cancer initiating novel hormonal therapies (NHTs): Real world evidence.
146 Background: Novel hormonal therapies (NHTs), abiraterone acetate, enzalutamide, apalutamide, and darolutamide, target...
Prognostic utility of tumor mutational burden in older adults (≥75 years) with bladder cancer: A TCGA geriatric oncology analysis.
834 Background: Older adults represent nearly half of bladder cancer diagnoses but are underrepresented in biomarker studi...
A retrospective evaluation of treatment patterns following cabozantinib treatment for advanced renal cancer: The CABONEXT study.
451 Background: Cabozantinib with nivolumab is considered as a standard of care in first-line treatment for metastatic ren...
Microplastics and prostate cancer.
379 Background: Plastics are ubiquitous in our environment. Tiny plastic particles called microplastics and nanoplastics (...
Real-world endpoints as surrogates for overall survival in metastatic bladder cancer.
693 Background: Overall survival (OS) remains the gold-standard endpoint in solid tumors, including metastatic bladder can...
Prevalence of major adverse cardiac events in men with prostate cancer receiving androgen deprivation therapy in real-world clinical practice.
107 Background: Androgen deprivation therapy (ADT) is the backbone treatment for advanced prostate cancer (PC), but it has...
Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.
423 Background: Novel MoAs remain an unmet need for patients with advanced ccRCC with PD after multiple therapies. Combina...
Treatment patterns and survival outcomes among lutetium 177–experienced patients with metastatic castration-resistant prostate cancer.
69 Background: Survival expectations for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) recei...
Pelvic lymph node risk stratification in prostate cancer: A machine learning approach toward a predictive nomogram.
349 Background: Pelvic lymph node involvement (PLNI) is a critical prognostic factor in PCa, guiding decisions regarding e...
Perioperative enfortumab vedotin plus pembrolizumab versus neoadjuvant pembrolizumab in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC): An IPD-based comparative analysis of KEYNOTE-905/EV-303 and PURE-01.
779 Background: Cisplatin-based chemotherapy is the standard neoadjuvant therapy for patients (pts) with MIBC. However, a...
Dose optimisation and PSMA receptor intensification with <sup>177</sup> Lu-PSMA-597 in metastatic castration-resistant prostate cancer (mCRPC): The randomised phase II OPTIMAL-PSMA trial.
TPS293 Background: [ 177 Lu]Lu-PSMA is a targeted radionuclide beta therapy in met...
POSTER: Evaluating the impact of virtual peer-led support groups on prostate cancer survivorship—The AnCan experience.
265 Background: Comprehensive prostate cancer (PCa) survivorship requires more than just clinical care, including educatio...
Second-line therapy after ipilimumab and nivolumab in advanced renal cell carcinoma: A multicenter real-world study (GUARDIANS).
437 Background: Ipilimumab plus nivolumab is a standard first-line therapy for intermediate and poor-risk patients with me...
First results of a dose-escalation study evaluating <i>Clostridium butyricum</i> MIYAIRI 588 (CBM588) with nivolumab/ipilimumab (nivo/ipi) in metastatic renal cell carcinoma (mRCC).
503 Background: CBM588 has shown potential to improve clinical outcomes when combined with immune checkpoint inhibitors (I...
Noninvasive fragmentomic profiling of plasma cell-free DNA (cfDNA) in metastatic prostate cancer (mPC): Associations with transcriptomic phenotypes and disease states.
260 Background: Current liquid biopsy assays yield few clinically actionable insights, because they measure discrete genom...
Description and management strategies of prespecified treatment emergent adverse events (TEAEs) amongst patients (pts) treated with 1L enfortumab vedotin (EV) + pembrolizumab (P) for la/mUC in a real-world setting.
671 Background: Based on EV-302 study results, EV+P is considered the standard of care therapy for 1L la/mUC. In EV-302, t...
Real-world utilization of tissue-free ctDNA monitoring in patients with prostate cancer.
98 Background: Circulating tumor DNA (ctDNA) monitoring provides an additional clinical tool for assessing treatment respo...
Discrepancies in the administration of sequential therapies for metastatic renal cell carcinoma: Real-world practice versus randomized controlled trials.
481 Background: While randomized controlled trials (RCTs) have established first-line standards for metastatic renal cell...
The efficacy and safety of disitamab vedotin plus immunotherapy in locally advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis.
774 Background: The combination of disitamab vedotin (DV), a novel human epidermal growth factor receptor 2 (HER2)-targeti...
Development and validation of a computational histology artificial intelligence (CHAI) prognostic biomarker in renal cell carcinoma.
546 Background: Artificial intelligence (AI)–based digital pathology has shown great promise in prostate and bladder cance...
Real-world genomic analysis of chemerin in prostate cancer (PCa) and correlation with markers of immune infiltration and activation.
110 Background: Chemerin, a leukocyte chemoattractant, signals through CMKLR1 on immune cells. Its role in tumor immunolog...